Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non–Small-Cell Lung Cancer with Activating EGFR Mutation
Conclusion: TLG can predict PFS and development of gefitinib resistance in EGFR-mutant NSCLC patients treated with first-line gefitinib. Baseline metabolic tumor burdens measured with TLG before first-line gefitinib will be of great help in predicting time to acquired resistance.
Source: Journal of Thoracic Oncology - Category: Cancer & Oncology Tags: Original Article Source Type: research
More News: Cancer | Cancer & Oncology | CT Scan | Lung Cancer | Non-Small Cell Lung Cancer | PET Scan | Study